The anti-Müllerian hormone (AMH) test estimates the pool of small growing ovarian follicles and is widely used to predict how the ovaries may respond to fertility medication. A higher result often predicts more eggs retrieved during stimulation, while a lower result often predicts fewer. AMH does not directly measure egg quality, prove infertility, or accurately predict whether someone will conceive naturally in a given month. Age remains a stronger guide to egg quality and miscarriage risk. AMH can be measured on most cycle days, but hormonal contraception, pregnancy, recent ovarian surgery, and some medical treatments can lower the result. High values are common in PCOS and can signal an increased risk of excessive response during stimulation. Laboratories use different assays and age-specific intervals, so interpretation should focus on the report, reproductive goals, ultrasound antral follicle count, and the planned treatment rather than a universal “good” AMH number.
- AMH estimates ovarian follicle quantity and predicts response to ovarian stimulation better than natural pregnancy.
- Low AMH can mean fewer eggs may be retrieved, but it does not mean pregnancy is impossible.
- High AMH often occurs with PCOS and may increase the risk of ovarian hyperstimulation during treatment.
- AMH can usually be drawn on any cycle day, although hormonal contraception may temporarily lower it.
- Age, antral follicle count, prior treatment response, and reproductive goals are essential for interpretation.
- AMH should not be used alone to deny fertility treatment or to predict the exact age of menopause.
Table of Contents
- What the AMH Test Measures
- Why the Test Is Ordered
- Preparation, Timing, and the Testing Process
- Normal Range and How Results Are Interpreted
- What High AMH Results Can Mean
- What Low AMH Results Can Mean
- How Results Fit With Other Hormones and Tests
- Next Steps After the Result
What the AMH Test Measures
AMH is produced by granulosa cells in preantral and small antral follicles. These follicles are not the eggs that will necessarily ovulate that month; they represent a visible portion of the remaining follicle pool. As the pool declines with age, AMH generally falls, often before FSH becomes persistently elevated.
The test is most established in assisted reproduction. It helps clinics choose a starting dose of gonadotropins and estimate low or high ovarian response. It is less reliable as a stand-alone test of natural fecundability because conception also depends on ovulation, sperm, tubes, uterus, timing, and embryo quality.
A hormone result is a measurement made under defined laboratory conditions, not a diagnosis by itself. The same concentration can carry different meaning at different ages, cycle stages, pregnancy stages, or times of day. Laboratories also use different analyzers, calibration systems, antibodies, and calculation methods. For that reason, the reference interval printed beside the result should take priority over a range copied from another report or website.
AMH is also used in selected assessments of PCOS, ovarian damage after surgery or chemotherapy, and differences in sexual development. Its meaning changes across these settings. A fertility-clinic interpretation should not be copied into pediatric or oncology care.
AMH is one component of an ovarian reserve test panel that may also include antral follicle count, FSH, and estradiol.
Why the Test Is Ordered
AMH is ordered when the likely ovarian response or remaining follicle pool will affect counseling, treatment planning, or risk assessment.
- Planning IVF, egg freezing, or another treatment that uses ovarian stimulation.
- Estimating the likelihood of a low or excessive response to fertility medicines.
- Assessing ovarian reserve after ovarian surgery, chemotherapy, radiation, or a condition that may affect the ovaries.
- Supporting a PCOS evaluation in adults when interpreted within accepted diagnostic criteria.
- Evaluating possible primary ovarian insufficiency as part of a broader workup, though AMH is not the primary diagnostic test.
- Counseling about reproductive timing when the limitations are explained clearly.
Routine AMH screening in people without infertility or a relevant medical reason can create false reassurance or unnecessary alarm. A high value does not preserve egg quality, and a low value does not establish that natural conception cannot occur. Decisions about egg freezing should include age, family plans, costs, procedure risks, and expected numbers of mature eggs, not AMH alone.
Interpretation starts with the reason the test was ordered. A clinician looking for an adrenal enzyme disorder uses different cutoffs and follow-up tests than a clinician evaluating irregular periods, infertility, menopausal symptoms, or androgen deficiency. The result should be read with symptoms, examination findings, age, reproductive stage, and related laboratory values rather than compared with one universal “optimal” number.
A broader fertility hormone panel may be appropriate when periods are irregular or infertility has more than one possible cause.
Preparation, Timing, and the Testing Process
AMH varies less across the menstrual cycle than FSH, estradiol, or progesterone, so it can usually be collected on any day.
- Confirm the reason for testing and whether the result will guide treatment, diagnosis, or counseling.
- List hormonal contraception, fertility drugs, pregnancy, lactation, ovarian surgery, chemotherapy, and supplements.
- Use the same laboratory and assay for serial testing when possible.
- Ask whether an antral follicle count ultrasound is planned and how the two measures will be combined.
- Do not stop contraception or delay needed treatment solely to obtain an AMH result without clinical advice.
Hormonal contraceptives can suppress AMH and antral follicle count in some users, especially with longer use. A clinician may repeat testing after a break when the result is unexpectedly low and the answer would change care. Pregnancy and the postpartum period also alter ovarian activity, making routine reserve interpretation less straightforward.
Before collection, provide a complete list of prescription medicines, over-the-counter products, supplements, contraceptives, fertility drugs, and hormone therapy. Do not stop prescribed treatment without instructions. Some products change hormone production, while others alter binding proteins or interfere with an immunoassay. High-dose biotin is a well-known source of interference in several hormone tests, although the direction and size of the error depend on the platform.
Acute illness can temporarily suppress or stimulate reproductive signaling. A test drawn during fever, major surgery, severe calorie restriction, or intense training may describe that temporary state rather than the person’s usual hormone function. When the clinical situation is stable and there is no urgent reason to test immediately, postponing or repeating the measurement can prevent an incorrect label.
Normal Range and How Results Are Interpreted
AMH is commonly reported in ng/mL or pmol/L. Approximate categories can help explain a report, but age-specific percentiles and the laboratory method are more useful than universal cutoffs.
| Approximate AMH | Common interpretation | Important limitation |
|---|---|---|
| Below about 0.5 ng/mL | Very low expected response in many stimulation protocols | Natural conception can still occur |
| About 0.5–1.0 ng/mL | Lower ovarian response may be expected | Age and antral follicle count refine the estimate |
| About 1.0–3.5 ng/mL | Often within a typical treatment-response range | No guarantee of egg quality or pregnancy |
| Above about 3.5–5.0 ng/mL | Higher response or PCOS may be considered | Cutoffs differ by assay and population |
| Very high for age | Risk of excessive response may be increased | Protocol and symptoms determine actual risk |
To convert approximately, 1 ng/mL equals about 7.14 pmol/L, but laboratories may calibrate assays differently. AMH naturally declines with age, so the same value has different implications at age 25 and age 42. A single result cannot reveal the exact number of eggs remaining.
A value close to a cutoff deserves more caution than a value that is clearly and repeatedly abnormal. Borderline results may move across the reference limit because of normal biologic variation, recent illness, sleep disruption, exercise, stress, or sample timing. Clinicians often repeat a test under better-controlled conditions before ordering imaging or beginning treatment. The repeat is most useful when the timing, medication list, and assay method are documented.
Trends can be useful when the same question is followed over time, but only when the measurements are reasonably comparable. A change between laboratories may reflect a method difference. A change after starting or stopping hormones may be expected. Record the laboratory, units, collection time, cycle day or pregnancy week, and relevant treatment so later results can be compared in context.
The FSH test may add information when measured with early-follicular estradiol, although it fluctuates more between cycles.
What High AMH Results Can Mean
High AMH usually reflects a larger number of small follicles. It is often a normal age-related finding or part of PCOS rather than a disease by itself.
- PCOS or polycystic ovarian morphology.
- Younger reproductive age and a naturally larger follicle pool.
- Granulosa-cell tumors in rare cases, usually with other clinical findings.
- Assay or population differences.
- Recovery after stopping a suppressive hormone treatment.
During IVF, high AMH predicts a stronger response and helps identify people who may need lower medication doses or an antagonist protocol to reduce ovarian hyperstimulation syndrome risk. Modern trigger and embryo-freezing strategies can reduce risk, but treatment still requires monitoring.
AMH alone should not diagnose PCOS in adolescents. In adults, current guidelines allow AMH as an alternative to ultrasound for defining polycystic ovarian morphology in specific diagnostic pathways, but it should not replace the full clinical criteria or be used as a single test.
Follow-up depends on symptoms and goals. Irregular cycles or androgen symptoms may prompt a PCOS evaluation. A very high or rising value with an ovarian mass requires specialist assessment, although this is uncommon.
When high AMH occurs with irregular ovulation and androgen excess, a PCOS hormone panel can help exclude mimicking conditions.
What Low AMH Results Can Mean
Low AMH means fewer small follicles were detected by the marker than expected for the comparison group. It is most useful for anticipating ovarian response, not declaring that pregnancy is impossible.
- Normal age-related decline in the follicle pool.
- Diminished ovarian reserve or primary ovarian insufficiency.
- Ovarian surgery, especially repeated endometrioma surgery.
- Chemotherapy, pelvic radiation, or gonadotoxic medical treatment.
- Temporary suppression associated with hormonal contraception or pregnancy.
- Individual biologic and assay variation.
A low result can influence treatment timing and medication dose. It may also support discussion of donor eggs or embryo banking when repeated response is poor. Yet some people with low AMH ovulate regularly and conceive without treatment. The result does not measure chromosome number in eggs or predict miscarriage independently of age.
Primary ovarian insufficiency is diagnosed mainly from menstrual disturbance and elevated FSH in the appropriate clinical setting. AMH may support the assessment, but an isolated low AMH in someone with regular cycles does not establish the diagnosis.
Discuss how the result changes a concrete plan. Repeating AMH frequently without a new clinical question rarely adds value because short-term changes can reflect assay variation rather than meaningful follicle loss.
When periods are absent or estrogen symptoms occur, a primary ovarian insufficiency panel is more diagnostic than AMH alone.
How Results Fit With Other Hormones and Tests
AMH, antral follicle count, FSH, and estradiol describe different parts of ovarian function. Agreement strengthens confidence; disagreement prompts review of timing, contraception, and the assay.
| Pattern | Likely interpretation | Clinical use |
|---|---|---|
| Low AMH + low antral follicle count | Reduced expected response | Plan stimulation and counsel about egg yield |
| High AMH + high antral follicle count | High response or PCOS pattern | Reduce hyperstimulation risk |
| Low AMH + regular cycles + normal FSH | Reserve marker is low, but ovulation may continue | Do not equate with sterility |
| Low AMH + high FSH + low estradiol | Ovarian insufficiency more likely | Evaluate menstrual history and causes |
| AMH lower on contraception | Possible reversible suppression | Repeat off treatment only if it will change care |
Prior ovarian response is often more informative than any reserve test. The number of mature eggs retrieved, fertilization, embryo development, and age-specific live-birth estimates guide later cycles. Reserve tests should improve planning, not serve as a pass-fail gate.
Next Steps After the Result
The best next step turns the AMH result into realistic counseling while preserving its limitations.
- Compare the value with the laboratory’s age-specific interval and confirm the units and assay.
- Combine AMH with antral follicle count, age, menstrual history, and prior response.
- Address reversible influences such as hormonal contraception when a repeat would change treatment.
- Complete the rest of the fertility evaluation rather than focusing only on ovarian reserve.
- Use high AMH to plan safer stimulation and low AMH to discuss expected egg yield and timing.
- Seek reproductive endocrinology advice when the result is unexpected, fertility is time-sensitive, or medical treatment may damage the ovaries.
For people facing chemotherapy or pelvic radiation, fertility-preservation referral should occur before treatment whenever possible; waiting for a second AMH can waste valuable time. For those trying to conceive, evaluation generally starts after 12 months under age 35, after 6 months at age 35 or older, or sooner with irregular cycles or known risk factors.
Bring the actual report to the follow-up visit rather than only recalling that the level was “high” or “low.” The report shows units, the laboratory interval, specimen type, and sometimes the assay method. Ask whether the result needs confirmation, whether a related hormone should be measured at the same time, and what finding would change management.
A useful plan defines the next step and its timing. That may be no action, a repeat test, a dynamic stimulation or suppression test, ultrasound, semen analysis, genetic testing, or referral to endocrinology, reproductive endocrinology, urology, or maternal-fetal medicine. It should also identify symptoms that warrant earlier contact instead of waiting for the routine appointment.
Rapidly progressive symptoms deserve faster evaluation than a mild, stable laboratory abnormality. Examples include sudden virilization, severe headache with visual change, signs of adrenal crisis, heavy bleeding with dizziness, or concerning pregnancy symptoms. The laboratory number may guide the workup, but urgent decisions are driven by the whole clinical picture.
Treatment should address the confirmed cause and the person’s goals. Lowering or raising a laboratory value without establishing why it is abnormal can hide an important condition or create new problems. Hormone therapy can affect fertility, blood counts, liver function, clot risk, bone health, and pregnancy, so monitoring plans should be individualized.
AMH abnormalities rarely create an emergency. Urgent care is instead based on symptoms such as severe pain, rapid abdominal swelling, shortness of breath, or reduced urination during fertility treatment, which can indicate ovarian hyperstimulation.
When a repeat measurement is planned, try to reproduce the conditions that matter for this test. Use the same laboratory when practical, note the collection time, and record any change in medicines or reproductive stage. Consistency does not remove all biologic variation, but it makes a true trend easier to distinguish from noise.
Reference intervals describe a population selected by the laboratory; they do not define a treatment target for every person. A result inside the interval can still require attention when symptoms are strong or when another hormone shows a clear mismatch. Conversely, a small deviation may not represent disease when the timing or clinical setting explains it.
A laboratory result can answer only the question built into the test. It may show hormone concentration, but it cannot by itself prove ovulation quality, egg quality, sperm production, placental health, or the cause of a symptom. Those conclusions usually require a combination of history, examination, imaging, and other targeted tests.
When fertility is the concern, age, duration of trying to conceive, menstrual pattern, pregnancy history, semen findings, and tubal or uterine factors often affect the plan as much as a single hormone value. Testing both partners in parallel can prevent months of delay and reduce the chance that an incidental hormone result distracts from a more direct cause.
When symptoms are being monitored rather than fertility, define the outcome that treatment is meant to improve. Examples include restoration of periods, relief of hot flashes, reduction of unwanted hair growth, recovery of sexual function, preservation of bone health, or safe progression of puberty. Laboratory monitoring is most useful when tied to one of these clinical outcomes.
People using nonprescription “hormone balance” products should mention them before testing. DHEA, progesterone creams, testosterone boosters, compounded preparations, and biotin can alter physiology or make results harder to interpret. Product labels may not reliably predict the dose absorbed, so the safest approach is to review the exact container or ingredient list with the clinician.
Results can also differ because laboratories report conventional and SI units. A value expressed in ng/dL cannot be compared directly with one expressed in nmol/L without a hormone-specific conversion. Always compare the number, unit, and interval together. This simple check prevents many apparent contradictions between reports.
An abnormal result can have emotional weight, especially during fertility treatment, pregnancy, or puberty evaluation. Ask the clinician to separate what is known from what remains uncertain. A clear explanation of the likely causes, the confirmation plan, and the time frame for action is more useful than trying to interpret every decimal place independently.
Clinicians also consider whether the test result agrees with the physical findings. A marked biochemical abnormality without expected symptoms may prompt confirmation with a more specific laboratory method. Strong symptoms with a normal result may lead to testing at a different time, measuring a related hormone, or looking for a nonhormonal cause.
The pace of change can be as important as the level itself. Slow changes over years commonly fit physiologic aging or a chronic endocrine condition. Changes over weeks or a few months raise more concern for a new medicine effect, pregnancy-related change, acute illness, or a hormone-producing lesion, especially when symptoms progress quickly.
No single follow-up pathway fits every abnormal value. Mild and explainable results may only need observation. Persistent or substantial abnormalities may require specialist review and tests chosen to locate the source of hormone production or the level of signaling failure. The sequence should be deliberate so that each test answers a specific unresolved question.
Keep a copy of the laboratory report and the order indication. The clinician needs more than the highlighted flag: the numeric value, unit, reference interval, specimen type, collection date and time, and any comment about the assay can change interpretation. A result copied into a patient portal message without those details may be impossible to compare with a later test. This documentation is especially important when care moves between a primary clinician, endocrinologist, fertility clinic, and hospital laboratory.
Before repeating testing, decide what the repeat is meant to resolve. It may confirm persistence, correct a timing error, remove a medication effect, or use a more specific assay. Repeating the same poorly timed test without changing the conditions often reproduces uncertainty rather than solving it. The clinician should also state what result would lead to observation, another laboratory test, imaging, or treatment.
Small deviations from a reference interval are common because the interval usually contains about 95% of a selected comparison population. Some healthy people fall outside it, while some people with disease fall inside it. The clinical importance depends on how far the value is from the limit, whether it persists, whether related hormones agree, and whether symptoms fit the physiology. A reference flag is therefore a prompt for interpretation, not proof of disease.
Hormone results are also affected by changes in binding proteins and metabolism. Liver disease, thyroid disease, kidney disease, pregnancy, body composition, and oral estrogen exposure can change measured concentrations without producing the same change in tissue effect. When a binding issue is suspected, the clinician may use a free or calculated hormone, a related binding protein, or a more specific laboratory method rather than interpreting the total concentration alone.
References
- Anti-Müllerian hormone for screening, diagnosis, evaluation, and prediction: A systematic review and expert opinions 2024 (Systematic Review)
- The Clinical Utility of Measures of Ovarian Reserve 2025 (Review)
- Fertility evaluation of infertile women: a committee opinion 2021 (Committee Opinion)
- Guideline for the prevention, diagnosis and treatment of infertility 2025 (Guideline)
- Guideline on premature ovarian insufficiency 2024 (Guideline)
Disclaimer
This information cannot predict an individual pregnancy or replace fertility evaluation. AMH ranges and treatment thresholds differ by assay and clinic. Discuss fertility timing, ovarian stimulation, and possible ovarian insufficiency with a qualified clinician.
